logo
Plus   Neg
Share
Email

Hugo Boss FY19 Profit Down, Lifts Dividend; Says Confident Of FY20, Beyond

German luxury fashion brand Hugo Boss AG (HUGSF.PK) reported Thursday that its fiscal 2019 net profit attributable to equity holders of the parent company declined to 205.11 million euros from last year's 236.15 million euros.

Earnings per share were 2.97 euros, down from 3.42 euros last year.

Consolidated net income excluding the impact of IFRS 16 was 212 million euros, down 10 percent.

Operating result or EBIT fell to 344.50 million euros from last year's 346.81 million euros. The company said the weak earnings mainly reflected lower than expected sales growth, increased markdown activity - particularly in North America, and additional investments in retail business.

Group sales increased to 2.88 billion euros from 2.80 billion euros last year.

Further, the company proposed dividend of 2.75 per share for the year, up 2 percent from last year.

Looking ahead, Chief Executive Officer Mark Langer said, "I am very confident that, together, we will achieve our targets for 2020 and beyond."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Avalon Furniture is recalling about 9,500 units of Cottage Town Bedroom Furniture collection sold through Rooms To Go due to violation of federal lead paint ban, the U.S. Consumer Product Safety Commission said in a statement. According to the agency, the base coat paint used on pieces within the furniture collection contains levels of lead that exceed the federal lead paint standard. Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Phase 3 trial of arthritis drug Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints. In the trial, Kevzara was added to best supportive care compared to best supportive care alone (placebo). The companies have stopped the U.S. trial. Shares of Moderna Inc. (MRNA) slipped over 5% on Thursday after a report claimed that the biotechnology company's late-stage trial for a coronavirus vaccine will be delayed. Moderna is developing mRNA-1273 in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). The...
Follow RTT